Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Recurrent Glioblastoma Multiforme
NCT02586857Phase 2Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Jan 2016
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in glioblastoma multiforme (GBM), sponsored by Acerta Pharma. Started Jan 2016; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02586857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586857.